1Taniquohi A,Nakai Y,Fukushiraa M,et al. Ultrasonographicallyassessed carotid atherosclerosis in Japanese type 2 diabetictients :role of nonesterified fatty acids. Metabolism,2002,51 :539-543.
2Paolisso G,Howard BV. Role of non-esterified fatty acids in thepathogenesis of type 2 diabetes mellitus. Diabet Med,1998,15:360-366.
3Carlsson M,Wessman Y,Almgren P,et al. High levels of Etnonesterified fatty acids are associated with increased familialrisk of cardiovascular disease. Arterioscler Throm Vase Biol,2000,20:1588-1594.
6Okada E,OidaK,Tada H,et al. Hyperhomocysteinemia is a riskfactor for coronary arteriosclerosis in Japanese patients with type 2diabetes. Diabetes Care,1999,22 :484-490.
2Susan C, Louis M, Vivian F. Hyperhomocysteinemia-an emerging and important risk factor for thromboebolic and cardiovascular disease. Clin Chem, 1996,106:709-722
3Jacob S, Paul FJ, Peter WF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA, 1993,270:2693-2698.
4Drzewoski J, Czupryniak L, Bud E. Total plasma homocysteine and insulin levels in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care, 1999,22:2097-2103.
5Lee WJ, Chen YT, Shen WH. Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens, 2000,13(1 pt):14-20.
6House JD, Jacobs RL, Stead LM, et al. Regulation of homocysteine metabolism. Adv Enzyme Regul, 1999,39:69-91.
5Giovanni Targher,Alessandro Mantovani, Isabella Pichiri. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes[J]. Clinical Science ,2013, 125(6) :301-309.
6Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease [J]. The Annals of Pharmacotherapy, 2010,44 ( 10 ) : 1655- 1659.
7Stefano Bonapace, Gianluea Perseghin, Giulio Molon. Non- alcoholic fatty liver disease is associated with left ventric- ular diastolic dysfunction in patients with type 2 diabetes[J]. Diabetes Care,2012,35 (2) :389-395.
8Sunder Mudaliar,Robert RH,Arun JS,et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liv- er disease[J]. Gastroenterology, 2013,145 (3) : 574-582.
9Nolan CJ. Failure of islet beta-cell compensation for in- sulin resistance causes type 2 diabetes: What causes non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Journal of Gastroenterology and Hep- atology,2010,25 (10) : 1594-1597.
10Konstantinos Tziomalos,Vassilios GA,Asterios Karagian- nis. Non-alcoholic fatty liver disease in type 2 diabetes : Pathogenesis and treatment options[J]. Current Vascu- lar Pharmacology,2012,10(2) : 162-172.
